Relaxin becomes upregulated during prostate cancer progression to androgen independence and is negatively regulated by androgens

The Prostate ◽  
2006 ◽  
Vol 66 (16) ◽  
pp. 1698-1709 ◽  
Author(s):  
Vanessa C. Thompson ◽  
Tanis G.W. Morris ◽  
Dawn R. Cochrane ◽  
John Cavanagh ◽  
Latif A. Wafa ◽  
...  
The Prostate ◽  
2015 ◽  
Vol 76 (2) ◽  
pp. 140-150 ◽  
Author(s):  
Huiyan Wang ◽  
Lixia Zhang ◽  
Ying Fu ◽  
Fang Fang ◽  
Yong Jiang ◽  
...  

The Prostate ◽  
2003 ◽  
Vol 55 (4) ◽  
pp. 239-246 ◽  
Author(s):  
Eva Corey ◽  
Janna E. Quinn ◽  
Kent R. Buhler ◽  
Peter S. Nelson ◽  
Jill A. Macoska ◽  
...  

Cell Research ◽  
2019 ◽  
Vol 29 (9) ◽  
pp. 773-775 ◽  
Author(s):  
Bohan Xu ◽  
Bing Song ◽  
Xiaodong Lu ◽  
Jung Kim ◽  
Ming Hu ◽  
...  

2006 ◽  
Vol 66 (16) ◽  
pp. 7929-7933 ◽  
Author(s):  
Hui Gao ◽  
Xuesong Ouyang ◽  
Whitney A. Banach-Petrosky ◽  
Michael M. Shen ◽  
Cory Abate-Shen

2005 ◽  
Vol 108 (4) ◽  
pp. 293-308 ◽  
Author(s):  
Daniel GIOELI

Prostate cancer is the most frequently diagnosed cancer among men and the second leading cause of male cancer deaths in the United States. When prostate cancer initially presents in the clinic, the tumour is dependent on androgen for growth and, therefore, responsive to the surgical or pharmacological ablation of circulating androgens. However, there is a high rate of treatment failure because the disease often recurs as androgen-independent metastases. Surprisingly, this late-stage androgen-independent prostate cancer almost always retains expression of the AR (androgen receptor), despite the near absence of circulating androgens. Although late-stage prostate cancer is androgen-independent, the AR still seems to play a role in cancer cell growth at this stage of disease. Therefore a key to understanding hormone-independent prostate cancer is to determine the mechanism(s) by which the AR can function even in the absence of physiological levels of circulating androgen. This review will focus on the role of growth factor signalling in prostate cancer progression to androgen independence and thus outline potential molecular areas of intervention to treat prostate cancer progression.


2005 ◽  
Vol 173 (4S) ◽  
pp. 126-127
Author(s):  
Yingming Li ◽  
Melissa Thompson ◽  
Zhu Chen ◽  
Bahaa S. Malaeb ◽  
David Corey ◽  
...  

2006 ◽  
Vol 175 (4S) ◽  
pp. 155-156
Author(s):  
Matthias D. Hofer ◽  
Sven Perner ◽  
Haojie Li ◽  
Rainer Kuefer ◽  
Richard E. Hautmann ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document